Abstract
Background
HPTN071 (PopART) was a cluster randomized trial conducted in Zambian and South African (SA) communities, between 2013–2018. The PopART intervention (universal HIV-testing and treatment (UTT) combined with population-level TB symptom screening) was implemented in 14 communities. The TREATS study (2017–2021) was conducted to evaluate the impact of the PopART intervention on TB outcomes. We report on the impact of the combined TB/HIV intervention on the incidence of TB infection in a cohort of adolescents and young adults (AYA) aged 15–24 years.
Methods
A random sample of AYA was enrolled between July 2018 and July 2019 in 7 intervention vs 7 standard-of-care communities. We collected questionnaire data on risk factors for TB, and blood for measuring TB infection using QuantiFERON (QFT) Plus. AYA were seen at months 12 and 24 with all procedures repeated. Primary outcome was incidence of TB infection comparing intervention and standard-of-care communities. An incident case was defined as a participant with QFT interferon-gamma response of < 0.2 IU/ml plasma (‘negative’) at baseline and a QFT interferon-gamma response of > = 0.7 IU/ml (‘positive’) at follow up.
Results
We enrolled 4,648 AYA, 2,223 (47.8%) had a negative QFT-plus result at baseline, 1,902 (85.6%) had a follow up blood sample taken at 12 months or 24 months. Among the 1,902 AYA, followed for 2,987 person-years, 213 had incident TB infection giving (7.1 per 100 person-years). TB infection incidence rates were 8.7 per 100 person-years in intervention communities compared to 6.0 per 100 person-years in standard-of-care communities. There was no evidence the intervention reduced the transmission of TB (incidence-rate-ratio of 1.45, 95%CI 0.97–2.15, p = 0.063).
Conclusion
In our trial setting, we found no evidence that UTT combined with TB active case finding reduced the incidence of TB infection at population level. Our data will inform future modelling work to better understand the population level dynamics of HIV and TB.
Funder
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
National Institute on Drug Abuse
Bill and Melinda Gates Foundation
National Institute of Mental Health
U.S. President’s Emergency Plan for AIDS Relief
European and Developing Countries Clinical Trials Partnership
Publisher
Public Library of Science (PLoS)
Reference50 articles.
1. WHO. Global tuberculosis report 2021 [Available from: https://www.who.int/publications/i/item/9789240037021
2. Ministry of Health Zambia. Zambia Population-based HIV Impact Assessment (ZAMPHIA) 2016: Final Report. Lusaka MoH, February 2019.
3. WHO. Global Tuberculosis Report 2020 [Available from: https://www.who.int/publications/i/item/9789240013131.
4. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects;LW Chang;The Lancet infectious diseases,2013
5. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update;R Granich;Current Opinion in HIV and AIDS,2010
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献